New and emerging pharmacologic treatments for MDD
Frontiers in Psychiatry · 08.08.2025 · 16
DOI: 10.3389/fpsyt.2025.1621887 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Psychiatry, online erschienen am 08.08.2025. Verfasst von Aslihan Uyar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Standardization of Computational Anatomy Techniques for Cognitive and Behavioral Sciences (SoCAT) Lab, Department of Psychiatry, Faculty of the Medic…. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Major depressive disorder (MDD) presents a significant global health challenge, characterized by a high prevalence and significant impact on quality of life. Traditional antidepressants fall short in terms of efficacy and onset speed, up to 60% of patients. This review delves into the new and emerging pharmacologic treatments for MDD, focusing on their mechanisms of action, clinical effectiveness, and potential to fill the gaps left by conventional therapies. New and emerging treatments in MDD have centered on different neurobiological pathways than the traditional monoaminergic systems. Ketamine and its enantiomer, S-ketamine, have been highlighted for their rapid antidepressant effects, which act through non-competitive N -methyl- d -aspartate (NMDA) receptor antagonism and other pathways involving synaptic plasticity. Clinical trials have demonstrated the ability of ketamine to quickly reduce symptoms, particularly in treatment-resistant cases, with effects noticeable within hours and lasting several days post-administration. Furthermore, the combination of dextromethorphan and bupropion has shown promise. This formulation leverages the NMDA receptor antagonism and sigma-1 receptor agonism of dextromethorphan, complemented by the inhibition of monoamine uptake and metabolism by bupropion, resulting in quicker and more durable antidepressant effects compared with monotherapy. Neurosteroids such as brexanolone and zuranolone, which target γ-aminobutyric acid (GABA)-A receptors, have emerged as effective treatments for postpartum depression. Brexanolone, administered via infusion, and zuranolone, available as an oral formulation, both have demonstrated efficacy in clinical settings. Novel treatments targeting opioid pathways, such as esmethadone, and selective kappa receptor antagonists offer new hope for addressing the symptoms of MDD through mechanisms not traditionally associated with antidepressant action.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Standardization of Computational Anatomy Techniques for Cognitive and Behavioral Sciences (SoCAT) Lab, Department of Psychiatry, Faculty of the Medicine, Ege University, Izmir, Türkiye.
- Department of Psychiatry, Mugla Sıtkı Kocman University Training and Research Hospital, Mugla, Türkiye.
Zitieren
APA
Uyar, A., & Gonul, A. S. (2025). New and emerging pharmacologic treatments for MDD. Frontiers in Psychiatry, 16. https://doi.org/10.3389/fpsyt.2025.1621887
Vancouver
Uyar A, Gonul AS. New and emerging pharmacologic treatments for MDD. Frontiers in Psychiatry. 2025;16. doi:10.3389/fpsyt.2025.1621887
BibTeX
@article{Uyar2025,
author = {Uyar, Aslihan and Gonul, Ali Saffet},
title = {New and emerging pharmacologic treatments for MDD},
journal = {Frontiers in Psychiatry},
year = {2025},
volume = {16},
doi = {10.3389/fpsyt.2025.1621887}
}
EUVIMED